Robin represents businesses, public pension funds, and end-payor plaintiffs in complex antitrust and commodities class actions, challenging monopolies, price fixing cartels, and other anticompetitive conduct.
Robin A. van der Meulen is a partner in DiCello Levitt’s New York office, where she represents clients in complex antitrust litigation. Prior to joining DiCello Levitt, Robin was a partner in a nationally-recognized antitrust practice group, where she gained more than a decade of experience litigating a wide variety of antitrust matters, including price-fixing, monopolization, benchmark and commodities manipulation, pay-for-delay agreements, and other anticompetitive practices.
Robin was appointed co-lead class counsel for end-payor plaintiffs in the Bystolic Antitrust Litigation, a pay-for-delay case pending in the Southern District of New York. She is also leading Novartis and Par Antitrust Litigation, another pay-for-delay case seeking to recover millions of dollars in overcharges relating to the hypertension drug Exforge on behalf of end-payor plaintiffs. Robin also represents end-payor plaintiffs in the Generic Pharmaceuticals Pricing Antitrust Litigation, a massive case against some of the biggest drug companies in the world alleging price-fixing and anticompetitive conspiracies.
Robin was previously an associate at Willkie Farr & Gallagher LLP, where she practiced antitrust and commercial litigation. She also served as a judicial intern in the United States Bankruptcy Court for the Eastern District of New York for Judge Elizabeth S. Stong.
Euromoney’s Women in Business Law Awards selected Robin as a finalist for Antitrust and Competition Lawyer of the Year.The Legal 500 recommends Robin for excellence in the field of Antitrust Civil Litigation and Class Actions, describing her as “persistent, persuasive, and well-respected by peers and opponents alike” and naming her a “Next Generation Partner.” She has been recognized as “Up and Coming” by Chambers & Partners USA and as a “Future Star” by Benchmark Litigation. She has also been selected to Benchmark’s “40 & Under Hot List” as one of “the best and brightest law firm partners” and someone who is “ready to take the reins.” Additionally, Robin was recognized by The Best Lawyers in America® in the Antitrust Law category.
Robin is an active member of the antitrust bar. She is the secretary and a member of the Executive Committee of the Antitrust Law Section of the New York State Bar Association (NYSBA), and a member of NYSBA House of Delegates. Robin is also a Vice Chair of the Insurance and Financial Services Committee of the Antitrust Section of the American Bar Association (ABA). Robin was previously a Vice Chair of the Antitrust Section’s Health Care & Pharmaceutical Committee of the ABA and the Executive Editor of that Committee’s Antitrust Health Care Chronicle. From 2012 to 2021, Robin was an editor of the Health Care Antitrust Week-In-Review, a weekly publication that summarizes antitrust news in the health care industry.
In re Bystolic Antitrust Litigation
In re Novartis and Par Antitrust Litigation (Exforge)
In re Generic Pharmaceuticals Pricing Antitrust Litigation
- Up and Coming, Chambers USA (2021)
- Future Star, Benchmark Litigation (2021-2022)
- 40 & Under Hot List, Benchmark Litigation (2021)
- Next Generation Partner, The Legal 500 (2021)
- Rising Star, New York Super Lawyers (2015-2020)
- Recognized in Antitrust Law, The Best Lawyers in America® (2022)
- Antitrust and Competition Lawyer of the Year Finalist, Euromoney’s Women in Business Law Awards (2021)
- “How I Made Partner: ‘It Takes a Well-Rounded Attorney to Make Partner,’ Says Labaton Sucharow’s Robin van der Meulen,” Law.com (February 2021)
- “An Update On Anti-Poach Enforcement and Class Actions,” Law360 (July 2018)
- “Cash or No Cash – That is No Longer the Question!” Antitrust Health Care Chronicle (April 2016)
- “What’s Located in Washington, Part of the Government and Rolling in Dough?” Bloomberg BNA Daily Report for Executives (March 2014)
- “Strategies for Handling Virtual Depositions,” Fundamentals of Taking and Defending Depositions 2021, Practising Law Institute (March 2021)
- “What’s New in Reverse Payment Litigation,” ABA Sections of Antitrust Law & Health Law (February 2021)
- “Fundamentals of Taking and Defending Depositions 2020,” Practising Law Institute, (March 2020)
- “Recent Developments in Health Care & Pharmaceuticals Q3 2019,” ABA Section of Antitrust Law (October 2019)
- Fundamentals of Taking and Defending Depositions 2019, Practising Law Institute (March 2019)
- “Recent Issues in Reverse Payments Litigations,” American Bar Association (September 2017)
- New York
- U.S. Court of Appeals, Second Circuit
- U.S. District Court, Eastern District of New York
- U.S. District Court, Southern District of New York
- New York State Bar Association Antitrust Law Section, Secretary and Executive Committee member
- New York State Bar Association House of Delegates, member
- American Bar Association Antitrust Law Section Insurance and Financial Services Committee, Vice Chair